再生元的股价上涨，因为它的收益超出预期，提高了股息，分析师的评论脾荒不一。 Regeneron's stock gains as it beats earnings estimates, raises dividend, amid mixed analyst reviews.

Regeneron Pharmaceuticals 第四季度机构投资者持股增加了 3.8%，几家公司调整了头寸。 Regeneron Pharmaceuticals saw a 3.8% rise in institutional investor holdings in the fourth quarter, with several firms adjusting their positions. 该公司的收益超出预期，每股 12.07 美元，并宣布季度股息为每股 0.88 美元。 The company beat earnings estimates, reporting $12.07 per share, and announced a quarterly dividend of $0.88 per share. 分析师给出了不同的评论，有一些上调和下调，但共识评级是“适度买入”，目标价为 973.13 美元。 Analysts have given mixed reviews, with some upgrades and downgrades, but the consensus rating is a "Moderate Buy" with a target price of $973.13.